Replies to post #68053 on Muscle Pharm Corporation (MSLPQ)

[Hunterdog]

I think we are saying the same thing.

From a BUYER'S point of view, they would get much more bang for their buck now as opposed to later.

From a SELLER'S point of view, they would much rather wait till the skies have cleared and everything is rosey.

Buyers often buy troubled companies.

Sellers always want to wait till there are no problems and the price is greatly elevated.

But we are saying the same thing, just from opposite sides of the equation.

[turokman]

With regards to the COCP 8K from the other day, I have to wonder a few things. Why did they sell the shares so cheap? It appears the last paragraph states that MusclePharm waived the lockup requirements as well - why was that requested?

It appears to me that the primary goal of the sale was to pay off the promissory note so that the issue with $MSLP taking over the lease and eviction problem.

I believe the current O/S is less than 12 million so we should find out soon who bought the shares (5% ownership). Depending on what the meaning of "non-affiliated" is - I would have to bet that it was Frost that bought up the shares.

On June 23, 2014, Cocrystal Pharma, Inc. (the "Company") sold 600,000 shares of MusclePharm Corporation ("Musclepharm") common stock to non-affiliated accredited investors for $5.4 million or $9.00 per share. As previously reported, the Musclepharm shares were acquired in connection with the sale of the Company's operating assets to Musclepharm (the "Transaction"). The purchasers agreed to a Lock-Up/Leak-Out Agreement which limits the sale of the shares to 12.5% per calendar month for an eight month period for any shares sold below $14.50 per share. The Company owns an additional 600,000 shares of Musclepharm common stock which it received as part of the Transaction, which shares are being held in escrow.

From the proceeds, the Company paid $2,626,290.72 to EverBank to acquire a promissory note (the "Note"), which is secured by a deed of trust on the property (the "Property") from which the Company previously conducted its principal operations. The Note was guaranteed by Biozone Laboratories, Inc., the Company's wholly-owned subsidiary. As previously reported, in connection with the Transaction, the Company assigned its lease to the Property to Musclepharm which triggered notice and approval requirements by the landlord and EverBank. The Company did not receive the requisite approval of either party. As the holder of the Note, the Company has notified the landlord that it consented to the change of control. See Form 10-Q for the three months ended March 31, 2014 for a description of the litigation filed by the landlord.

In connection with the sale of shares and pay-off of the Note, Musclepharm agreed to waive the Lock-Up/Leak-Out requirements under the Transaction with respect to the 600,000 shares sold by the Company to the purchasers